Early access
Sign in
Taking people in United StatesPhase 2

Tests iloperidone in adults with uncontrolled high blood pressure

Tests the drug iloperidone against a placebo in adults with uncontrolled high blood pressure.

Key facts

Who runs it
Vanda Pharmaceuticals
Where
Burke, Carrollton, Charleston, Chula Vista, Cincinnati, Columbus, Doral, Dublin, El Dorado, Fort Myers, Hazelwood, Kinston, Las Vegas, Lexington, Mount Kisco, Norfolk, Norman, Oak Brook, Oklahoma City, Phoenix, Rochester, Salt Lake City, Tempe, Tinley Park, Tucson, Valencia, Walnut Creek, and Wichita, United StatesSee the 28 sites
Trial code
Registry title
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
Status
Recruiting
Phase
Phase 2
People taking part
240 people, planned
Started
15 Sept 2025
Expected to end
Nov 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • iloperidone
  • Placebo
Record updated
27 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 65 whose blood pressure is still high even though they take blood pressure medicine.

Age
18 to 65 years
Sex
All sexes can join.
Disease stage
Uncontrolled hypertension: seated systolic blood pressure (SiSBP) of 130 mmHg or higher. Severe (Grade 3) hypertension is not allowed.
Earlier treatment
Must have taken 1 or more blood pressure medicines for more than 8 weeks, with blood pressure still high.

Main reasons for not taking part

  • Confirmed Grade 3 (severe) hypertension: SiSBP 180 mmHg or higher, or SiDBP 120 mmHg or higher
  • Unstable heart disease
  • Kidney insufficiency

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • SiSBP >/= 130 mmHg despite >8 weeks treatment w/ 1 or more antihypertensive therapies

Who cannot take part

  • Confirmed Grade 3/severe hypertension (SiSBP >/= 180 mmHg, SiDBP >/= 120 mmHg), unstable cardiac disease, renal insufficiency

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in United States

  • Burke, VirginiaHospital not named in the registryContact: Vanda Pharmaceuticals, Inc.Taking people
  • Carrollton, TexasHospital not named in the registryContact: Vanda Pharmaceuticals, Inc.Not yet recruiting
  • Charleston, South CarolinaHospital not named in the registryContact: Vanda Pharmaceuticals, Inc.Taking people
  • Chula Vista, CaliforniaHospital not named in the registryContact: Vanda Pharmaceuticals, Inc.Taking people
  • Cincinnati, OhioHospital not named in the registryContact: Vanda Pharmaceuticals, Inc.Taking people
  • Columbus, GeorgiaHospital not named in the registryContact: Vanda Pharmaceuticals, Inc.Taking people
  • Doral, FloridaHospital not named in the registryContact: Vanda Pharmaceuticals, Inc.Not yet recruiting
  • Dublin, CaliforniaHospital not named in the registryContact: Vanda Pharmaceuticals, Inc.Taking people
  • El Dorado, KansasHospital not named in the registryContact: Vanda Pharmaceuticals, Inc.Taking people
  • Fort Myers, FloridaHospital not named in the registryContact: Vanda Pharmaceuticals, Inc.Taking people
  • Hazelwood, MissouriHospital not named in the registryContact: Vanda Pharmaceuticals, Inc.Taking people
  • Kinston, North CarolinaHospital not named in the registryContact: Vanda Pharmaceuticals, Inc.Taking people
  • Las Vegas, NevadaHospital not named in the registryContact: Vanda Pharmaceuticals, Inc.Not yet recruiting
  • Lexington, KentuckyHospital not named in the registryContact: Vanda Pharmaceuticals, Inc.Taking people
  • Mount Kisco, New YorkHospital not named in the registryContact: Vanda Pharmaceuticals, Inc.Not yet recruiting
  • Norfolk, VirginiaHospital not named in the registryContact: Vanda Pharmaceuticals, Inc.Taking people
  • Norman, OklahomaHospital not named in the registryContact: Vanda Pharmaceuticals, Inc.Taking people
  • Oak Brook, IllinoisHospital not named in the registryContact: Vanda Pharmaceuticals, Inc.Taking people
  • Oklahoma City, OklahomaHospital not named in the registryContact: Vanda Pharmaceuticals, Inc.Not yet recruiting
  • Phoenix, ArizonaHospital not named in the registryContact: Vanda Pharmaceuticals, Inc.Not yet recruiting
  • Rochester, New YorkHospital not named in the registryContact: Vanda Pharmaceuticals, Inc.Not yet recruiting
  • Salt Lake City, UtahHospital not named in the registryContact: Vanda Pharmaceuticals, Inc.Not yet recruiting
  • Tempe, ArizonaHospital not named in the registryContact: Vanda Pharmaceuticals, Inc.Taking people
  • Tinley Park, IllinoisHospital not named in the registryContact: Vanda Pharmaceuticals, Inc.Taking people
  • Tucson, ArizonaHospital not named in the registryContact: Vanda Pharmaceuticals, Inc.Not yet recruiting
  • Valencia, CaliforniaHospital not named in the registryContact: Vanda Pharmaceuticals, Inc.Not yet recruiting
  • Walnut Creek, CaliforniaHospital not named in the registryContact: Vanda Pharmaceuticals, Inc.Taking people
  • Wichita, KansasHospital not named in the registryContact: Vanda Pharmaceuticals, Inc.Taking people

About the trial

What the trial wants to find out

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension

The 2 groups in the trial

  • Experimental/IloperidoneTreatment being tested

    Treatment: iloperidone

  • Placebo ComparatorPlacebo, for comparison

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
Plain-language title
Tests iloperidone in adults with uncontrolled high blood pressureGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07090161, who can take part
Record updated
27 February 2026